Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading ...
Cingulate Inc. (NASDAQ: CING) is a clinical-stage biopharmaceutical company headquartered in Kansas City, Kansas, founded in 2012. The company's core mission is to address unmet needs in central nervous system (CNS) disorders through its innovative Precision Timed Release (PTR) drug delivery platform, which enables the development of medications with optimized ...Cingulate Inc. (NASDAQ: CING) is a clinical-stage biopharmaceutical company headquartered in Kansas City, Kansas, founded in 2012. The company's core mission is to address unmet needs in central nervous system (CNS) disorders through its innovative Precision Timed Release (PTR) drug delivery platform, which enables the development of medications with optimized release profiles for enhanced efficacy, tolerability, and patient compliance.
Cingulate's pipeline is centered on three key candidates. CTx-1301 (dexmethylphenidate) is the lead product candidate for ADHD, currently in Phase 3 clinical trials. CTx-1302 (dextroamphetamine) is another ADHD candidate also advancing through Phase 3. Additionally, the company is developing CTx-2103, a candidate for anxiety disorders, which is in earlier stages of development. The PTR platform differentiates Cingulate by allowing for a single-dose, multi-release profile that could potentially replace multiple daily doses, improving patient adherence and outcomes.
As of the latest reported period (TTM data from the financial overview), Cingulate has 14 full-time employees, reflecting its clinical-stage status with a lean operational structure. The company is led by CEO and co-founder Shane J. Schaffer, a 25-year pharmaceutical industry veteran with extensive experience in drug development and commercialization. Financially, Cingulate is pre-revenue, with no product sales yet. Its financial metrics show negative profitability ratios (e.g., net profit margin and return on equity are negative), indicating ongoing investment in R&D. The company's cash position and working capital (approximately $25.9 million in cash as of March 31, 2026, per a recent report) are critical to funding clinical trials and advancing its pipeline.
Cingulate trades on the NASDAQ Capital Market with a market cap of around $70.2 million (as of the latest snapshot). Key financial ratios include a current ratio of 2.547, indicating sufficient short-term liquidity, and a debt-to-equity ratio of 0.394, suggesting a moderate use of leverage. The company's burn rate is high, with a negative free cash flow (FCF) of about -$13.8 million (FCF to equity) over the trailing twelve months, reflecting its heavy investment in R&D and clinical operations. Despite these losses, the company's PTR technology has significant potential, and its progress in Phase 3 trials for ADHD candidates positions it well for potential future commercialization. Overall, Cingulate's strategic focus, experienced leadership, and proprietary platform make it a notable player in the CNS biotech space, though it remains dependent on successful clinical outcomes and additional financing.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-22.4M
-35.6%
+37.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-17.4M
+6.7%
+14.4%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
350.2%
+412.1%
-31.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
1.16x
-54.3%
+37.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
